MRKR (Marker Therapeutics) Other Current Payables: $1.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MRKR Marker Therapeutics Inc MRKR
30 GF Score
Price $1.20
! 1 Warning Sign
View Full Analysis

What is Marker Therapeutics Other Current Payables?

Marker Therapeutics MRKR -0.01% 30 Other Current Payables is $1.00 Mil as of Mar. 2026. GuruFocus rates MRKR with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Marker Therapeutics's Other Current Payables for the quarter that ended in Mar. 2026 was $1.00 Mil.

Marker Therapeutics's quarterly Other Current Payables declined from Sep. 2025 ($0.33 Mil) to Dec. 2025 ($-0.00 Mil) but then increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($1.00 Mil).

Marker Therapeutics's annual Other Current Payables increased from Dec. 2023 ($1.33 Mil) to Dec. 2024 ($1.71 Mil) but then declined from Dec. 2024 ($1.71 Mil) to Dec. 2025 ($-0.00 Mil).

Marker Therapeutics Other Current Payables Related Terms

Marker Therapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Marker Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marker Therapeutics Other Current Payables Chart

Marker Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.33 1.71 -0.00

Marker Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.66 0.33 -0.00 1.00
MRKR
30GF Score
Marker Therapeutics Inc MRKR
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marker Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $1.00 Mil mean?
Marker Therapeutics (MRKR) has a Other Current Payables of $1.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Marker Therapeutics and its competitors.
Is Marker Therapeutics' Other Current Payables too high?
Marker Therapeutics' current Other Current Payables is $1.00 Mil. Overall, Marker Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Marker Therapeutics' Other Current Payables compare to NCEL and HOWL?
Marker Therapeutics' Other Current Payables of $1.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Marker Therapeutics and its competitors. Marker Therapeutics's current Other Current Payables is $1.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marker Therapeutics stock overvalued right now?
Marker Therapeutics (MRKR) has a current Other Current Payables of $1.00 Mil. The current Other Current Payables is $1.00 Mil. Marker Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Marker Therapeutics (MRKR), the current Other Current Payables is $1.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marker Therapeutics Business Description

Other Exchanges GX1:Germany
Address 2450 Holcombe Boulevard, TMC Partners Office 1.311, Houston, TX, USA, 77021
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
30GF Score

Get the complete analysis for MRKR

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.20
Price